The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Association between Statin Use and Alzheimer’s Disease
Abstract
Context: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been associated with a decreased risk for Alzheimer’s disease (AD). Objective: To evaluate the association between statin use and AD adjusted for comorbid medical conditions. Design: A nested case-control study. Patients: Patients at the Veterans Affairs Medical Center in Birmingham, Ala., USA with a new diagnosis of AD (cases) between 1997 and 2001 (n = 309) and age-matched non-AD controls (n = 3,088). Main Outcome Measure: Odds ratio for association between AD and statin use. Results: Statin users had a 39% lower risk of AD relative to nonstatin users (odds ratio 0.61, 95% confidence interval 0.42–0.87). This association appeared to be modified by the presence of certain chronic medical conditions (i.e., hypertension, ischemic heart disease and cerebrovascular disease) in that the reduced risk was observed among those with these diseases, whereas no association was observed among those without any of these conditions. Conclusions: In this study, following adjustment for confounding factors, a statistically significant inverse association between statin use and AD was observed. The results lend support to looking at AD outcomes in trials of statins to further evaluate their possible beneficial effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dietary fat intake and the risk of incident dementia in the Rotterdam study
Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C. M., Hofman, A., & Breteler, M. M. B. (1997) · Annals of Neurology · doi:10.1002/ana.410420514 · Cited by 895
Cited by
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Haag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393
Vascular risk factors, cognitve decline, and dementia
Hanon, O. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1839 · Cited by 313
Cancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Turgeon, J. L., Carr, M. C., Maki, P. M., Mendelsohn, M. E., & Wise, P. M. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0020 · Cited by 264
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193
Vascular Dementia Prevention: A Risk Factor Analysis
Román, G. C. (2005) · Cerebrovascular Diseases · doi:10.1159/000089361 · Cited by 150
Barone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86
Statins use and risk of dementia: A dose–response meta analysis
Zhang, X., Wen, J., & Zhang, Z. (2018) · Medicine · doi:10.1097/md.0000000000011304 · Cited by 78
Statins induce differentiation and cell death in neurons and astroglia
März, P., Otten, U., & Miserez, A. R. (2007) · Glia · doi:10.1002/glia.20422 · Cited by 75
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Pitavastatin decreases tau levels via the inactivation of Rho/ROCK
Hamano, T., Yen, S.-H., Gendron, T., Ko, L.-W., & Kuriyama, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.020 · Cited by 49
Statins: drugs for Alzheimer’s disease?
Eckert, G. P., Wood, W. G., & Müller, W. E. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0273-1 · Cited by 46
Li, L., Cao, D., Desmond, R., Rahman, A., Lah, J. J., Levey, A. I., & Zamrini, E. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000164271 · Cited by 45
Self-citationCholesterol in Alzheimer’s Disease and other Amyloidogenic Disorders
Harris, J. R., & Milton, N. G. N. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_2 · Cited by 44
Metadata
- Authors
- Zamrini, E., McGwin, G., & Roseman, J. M.
- Venue
- Neuroepidemiology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 23
- Issue
- 1-2
- Pages
- 94-98
- ISSN
- 0251-5350 (ISSN-L)
- 1423-0208
- OpenAlex
- W2046718416
- Cited by
- 202
- References
- 1
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.